Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy
about
"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2- and ER+HER2+) breast cancers.Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.Prognostic significance of clinicopathological factors in early breast cancer: 20 years of follow-up in a single-center analysis.
P2860
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Long-term hazard of recurrence ...... treated with anti-HER2 therapy
@ast
Long-term hazard of recurrence ...... treated with anti-HER2 therapy
@en
type
label
Long-term hazard of recurrence ...... treated with anti-HER2 therapy
@ast
Long-term hazard of recurrence ...... treated with anti-HER2 therapy
@en
prefLabel
Long-term hazard of recurrence ...... treated with anti-HER2 therapy
@ast
Long-term hazard of recurrence ...... treated with anti-HER2 therapy
@en
P2093
P2860
P50
P1476
Long-term hazard of recurrence ...... treated with anti-HER2 therapy
@en
P2093
Aman U Buzdar
Beverly Moy
Deborah Lindquist
Dianne M Finkelstein
Erica Rappold
Frances Boyle
Ian E Smith
Joyce O'Shaughnessy
Kathleen I Pritchard
Miguel Martin
P2860
P2888
P356
10.1186/S13058-015-0568-1
P577
2015-04-16T00:00:00Z
P6179
1003613394